DOCSLIB.ORG

Expulsion of a Uterine Myoma in a Patient Treated with Ulipristal Acetate Frederic Chantraine1, Gaelle Poismans1, Julia Nwachuku2, Elke Bestel2 & Michelle Nisolle1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expulsion of a Uterine Myoma in a Patient Treated with Ulipristal Acetate Frederic Chantraine1, Gaelle Poismans1, Julia Nwachuku2, Elke Bestel2 & Michelle Nisolle1 CASE REPORT Expulsion of a uterine myoma in a patient treated with ulipristal acetate Frederic Chantraine1, Gaelle Poismans1, Julia Nwachuku2, Elke Bestel2 & Michelle Nisolle1 1Department of Obstetrics and Gynecology, CHR Citadelle, University of Liege, Liege, Belgium 2PregLem S.A., Geneva, Switzerland Correspondence Key Clinical Message Frederic Chantraine, Department of Obstetrics and Gynecology, University of Description of a spontaneous expulsion of a submucosal myoma in a patient Liege, CHR Citadelle, Blv 12eme de Ligne 1, treated with ulipristal acetate. 4000 Liege, Belgium. Tel: +32 4 223 89 02; Fax: +32 4 224 00 05; Keywords E-mail: [email protected] Expulsion, myoma, selective progesterone receptor modulator, ulipristal acetate. Funding Information No sources of funding were declared for this study. Received: 16 September 2014; Revised: 28 October 2014; Accepted: 4 December 2014 Clinical Case Reports 2015; 3(4): 240–242 doi: 10.1002/ccr3.211 Introduction Case History Ulipristal acetate is a selective progesterone receptor modu- This report concerns a gravida 2 para 2 patient aged 45 lator (SPRM). It has clinical applications in emergency con- with no relevant medical–surgical history who had been traception and presurgical treatment of uterine myomas [1]. suffering from menometrorrhagia for 6 months. She had Uterine myomas are the most common pelvic tumors been using estrogen–progestin contraception (ethinyl- â in women [2] and are frequently responsible for pre- estradiol 0.02 mg, desogestrel 0.15 mg; Deso20 ) for menopausal menometrorrhagia and pelvic pain. The most 6 months. Menorrhagia treatment with tranexamic acid â common treatment options include surgical interventions (Exacyl ) had proven ineffective. A transvaginal ultra- such as hysterectomy or myomectomy. A study on hyster- sound exam diagnosed a polyfibromatous uterus (>four ectomy patients found myomas in 77% of hysterectomy myomas with diameters of between 43 and 15 mm). specimens [3]. Several drugs have been shown to be bene- Participation in the PEARL III study (a phase III, random- ficial in preparation for myomectomy or vaginal hysterec- ized, double-blind clinical study) was suggested. This study tomy. The effects sought are a reduction in the size of involves the administration of UPA at a dose of 10 mg per myomas and an improvement in the patient’s general day for 3 months. The patient is then allocated, by randomi- health by stopping the menorrhagia. zation, either a progestin (norethisterone acetate [NETA] Clinical studies are currently underway which aim 10 mg) or a placebo for a period of 10 days. This cycle is to examine the benefits of ulipristal acetate (UPA) treat- administered once in total and then followed by an optional ment on myomas, assessing improvement of symptoms, extension study, which repeats the UPA/NETA or UPA/pla- bleeding profile, and quality of life. It is in the context of cebo course three more times. Each treatment cycle is sepa- the PEARL III study (PGL4001’s Efficacy Assessment in rated by an “off-drug interval” allowing for return of Reduction of Symptoms due to uterine Leiomyomata III) menstruation and a full menstrual cycle. The aim of this study [4] that we report a case of spontaneous expulsion of a was to demonstrate the efficacy and safety of using UPA as a uterine myoma in a patient treated with UPA. long-term intermittent treatment of uterine myomas. 240 ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. F. Chantraine et al. Expulsion of a uterine myoma Outcome and Follow-up After study enrolment, the patient was given the study medication between September 2010 and September 2011. Amenorrhea was achieved after 3 days and persisted while UPA was being taken, apart from intervals when the med- ication was suspended. No adverse effects were noted and clinical monitoring, as well as routine laboratory tests, was normal. The sizes of the three largest myomas and the thickness of the endometrium were measured regu- larly via ultrasound (Fig. 1). A continuous decrease in size of the myomas was observed over the study period. The expulsed myoma was not one of those followed by ultrasound measurements; however, we can assume a sim- ilar size reduction. Figure 2. Transvaginal ultrasound, sagittal view of the cervix: 21 mm Endometrial biopsies, repeated several times within the myoma in the external orifice of the cervix. The vascular end-foot context of the study, showed no abnormalities when ascends to the cervical canal. The arrow shows the internal opening of the cervix. examined histologically. At the follow-up visit of September 2011, the endova- ginal ultrasound indicated that a myoma was in the pro- size) with no deleterious effect on the endometrium cess of being expelled at the cervix uteri (Fig. 2). A [6–8]. gynecological exam confirmed the presence of the myoma Three recent publications have demonstrated the effect in the endocervix. The diagnosis of spontaneous expul- of UPA, derived from 19-norprogesterone, on the control sion of submucosal myoma was postulated. Pedicle tor- of menorrhagia related to uterine myomatosis and on the sion enabled the myoma to be extracted in the outpatient reduction in size of myomas [4, 9, 10]. UPA is an SPRM, clinic, with no complications or excessive bleeding during which acts as a progesterone receptor antagonist and can the procedure. also act as an agonist [5, 11–13] in certain conditions. It Anatomopathological analysis confirmed the diagnosis acts specifically on the progesterone receptor with no of a submucosal myoma of 25 9 20 9 18 mm. The clinically relevant antiglucocorticoid activity (less than endometrium was at that time in a state of progesterone mifepristone, a 19-nortestosterone derivative [14]). impregnation and had a secretory appearance. Myoma expulsions reported in the published literature are mainly expulsions secondary to postembolization Discussion necrosis. In addition, some descriptions of myoma expul- sion following treatment with GnRH agonists have been There is a vast amount of literature published on the published [15–17]. This is the first incidence of myoma treatment of uterine myomas. The growth of myomas expulsion under SPRM treatment to our knowledge. The is not only estrogen dependent but is also influenced link between the administration of UPA and expulsion by progesterone [5]. Several SPRMs have shown an of the myoma in our case is not clear. In in vitro models antagonist effect on myomagrowth(reductionin of myoma cell cultures, UPA has antiproliferative, (A) (B) Figure 1. Transvaginal ultrasound, sagittal view of the uterus: two subserosal myomas in the posterior wall. (A) before UPA treatment, (B) after UPA-treatment. UPA, ulipristal acetate. ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 241 Expulsion of a uterine myoma F. Chantraine et al. 1 proapoptotic and antifibrotic effects [18]. Therefore, we progesterone receptor modulator CP8947 inhibits 2 theorize that a reduction in the size of the myoma causes leiomyoma cell proliferation without adversely affecting 3 the submucosal myoma to separate from the myometrium endometrium or myometrium. J. Steroid Biochem. Mol. 4 and the adjacent endometrium. Then, the ischemic submu- Biol. 122:279–286. 5 cosal myoma is expelled by contractions of the myometri- 7. Ohara, N., A. Morikawa, W. Chen, J. Wang, D. A. 6 um, as in a pregnancy that terminates in the first trimester. DeManno, K. Chwalisz, et al. 2007. Comparative effects of 7 In order to understand the molecular mechanism SPRM asoprisnil (J867) on proliferation, apoptosis, and 8 responsible for the reported persistence, for several months the expression of growth factors in cultured uterine 9 after treatment, of the beneficial effect of UPA on myoma leiomyoma cells and normal myometrial cells. Reprod. Sci. 10 size [10], further studies are required. Optimal manage- 14:20–27. 11 ment of uterine myomatosis remains a real challenge in 8. Chwalisz, K., M. C. Perez, D. Demanno, C. Winkel, G. 12 gynecology. It is important to be alert to the frequency of Schubert, and W. Elger. 2005. Selective progesterone receptor 13 this disease and to the presentation of its classic clinical modulator development and use in the treatment of – 14 symptoms. Despite the abundance of published literature leiomyomata and endometriosis. Endocr. Rev. 26:423 438. 15 on this disease, there are still numerous pathways to be 9. Donnez, J., T. F. Tatarchuk, P. Bouchard, L. Puscasiu, N. 16 explored, particularly with regard to drug treatment. To F. Zakharenko, T. Ivanova, et al. 2012. Ulipristal acetate 17 date, no molecule has resulted in a permanent therapeutic versus placebo for fibroid treatment before surgery. N. – 18 solution. UPA may offer an interesting and reassuring alter- Engl. J. Med. 366:409 420. 10. Donnez, J., J. Tomaszewski, F. Vazquez, P. Bouchard, B. 19 native and longer term studies with UPA are ongoing. Lemieszczuk, F. Baro, et al. 2012. Ulipristal acetate versus 20 leuprolide acetate for uterine fibroids. N. Engl. J. Med. 21 Conclusion 366:421–432. 22 11. Pintiaux, A., N. Chabbert-Buffet, and J. M. Foidart. 2009. 23 This case describes the potential of UPA to result in size Gynaecological uses of a new class of steroids: the selective 24 reduction of a myoma, which can result in the expulsion progesterone receptor modulators. Gynecol. Endocrinol. 25 of a submucosal myoma. 25:67–73. 26 12. Spitz, I. M. 2003. Progesterone antagonists and 27 Conflict of Interest progesterone receptor modulators: an overview. Steroids 28 68:981–993. 29 None declared. 13. Chabbert-Buffet, N., G. Meduri, P. Bouchard, and I. M. 30 Spitz. 2005. Selective progesterone receptor modulators References 31 and progesterone antagonists: mechanisms of action and 32 1.
Load more

Recommended publications
  • Abnormal Uterine Bleeding: Strategies for Management”
    PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women.
    [Show full text]
  • Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
    Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Asoprisnil: a Selective Progesterone Receptor Modulator
    Molecules of the Millennium Asoprisnil: A selective progesterone receptor modulator Progesterone is a hormone that is secreted by the corpus agonist–antagonist at progesterone receptors. Asoprisnil has luteum, placenta, and in minimal quantities by the testis and an antagonistic effect on the endometrium, ovary, and breast adrenal cortex. The important function of progesterone is to tissue. It has no effect or partial agonistic effect on myometrium sustain pregnancy. Large doses of progesterone inhibit LH of pregnant uterus, whereas in myometrium of leiomyoma it surge and potentiate the inhibitory effect of estrogen on acts as an antagonist. hypothalamus–pituitary axis, preventing ovulation. Therefore, On endometrium synthetic substances which are agonist at progesterone The selective progesterone receptor modulators cause receptor called “progestins” were developed, and these atrophy of the endometrium. Both selective progesterone substances became an essential constituent of oral receptor modulators and progesterone antagonists make the contraceptive pills. Progestins are mitogenic for breast blood vessels that supply blood to the endometrium robust, epithelium and increase mammographic shadow. Clinical trials whereas they become fragile with progestins. Both have shown that progestins and estrogens, and not estrogen progesterone antagonists and SPRMs cause amenorrhea. But alone, cause an increased incidence of breast cancer in the way in which both these group of drugs cause amenorrhea postmenopausal women.[1,2] Progesterone receptor
    [Show full text]
  • EC313-A Tissue Selective SPRM Reduces the Growth and Proliferation of Uterine Fbroids in a Human Uterine Fbroid Tissue Xenograft Model Hareesh B
    www.nature.com/scientificreports OPEN EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fbroids in a human uterine fbroid tissue xenograft model Hareesh B. Nair1*, Bindu Santhamma1, Kalarickal V. Dileep2, Peter Binkley3, Kirk Acosta1, Kam Y. J. Zhang 2, Robert Schenken3 & Klaus Nickisch1 Uterine fbroids (UFs) are associated with irregular or excessive uterine bleeding, pelvic pain or pressure, or infertility. Ovarian steroid hormones support the growth and maintenance of UFs. Ulipristal acetate (UPA) a selective progesterone receptor (PR) modulator (SPRM) reduce the size of UFs, inhibit ovulation and lead to amenorrhea. Recent liver toxicity concerns with UPA, diminished enthusiasm for its use and reinstate the critical need for a safe, efcacious SPRM to treat UFs. In the current study, we evaluated the efcacy of new SPRM, EC313, for the treatment for UFs using a NOD-SCID mouse model. EC313 treatment resulted in a dose-dependent reduction in the fbroid xenograft weight (p < 0.01). Estradiol (E2) induced proliferation was blocked signifcantly in EC313-treated xenograft fbroids (p < 0.0001). Uterine weight was reduced by EC313 treatment compared to UPA treatment. ER and PR were reduced in EC313-treated groups compared to controls (p < 0.001) and UPA treatments (p < 0.01). UF specifc desmin and collagen were markedly reduced with EC313 treatment. The partial PR agonism and no signs of unopposed estrogenicity makes EC313 a candidate for the long-term treatment for UFs. Docking studies have provided a structure based explanation for the SPRM activity of EC313. Te unmet need for medical management of uterine fbroids (UFs) has led to the discovery of various novel agents in recent years.
    [Show full text]
  • Selective Progesterone Receptor Modulators in Gynaecological Therapies
    65 1 Journal of Molecular H O D Critchley and SPRMs in gynaecological 65:1 T15–T33 Endocrinology R Chodankar therapies THEMATIC REVIEW 90 YEARS OF PROGESTERONE Selective progesterone receptor modulators in gynaecological therapies H O D Critchley and R R Chodankar MRC Centre for Reproductive Health, The University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh Bioquarter, Edinburgh, UK Correspondence should be addressed to H O D Critchley: [email protected] This review forms part of a special section on 90 years of progesterone. The guest editors for this section are Dr Simak Ali, Imperial College London, UK, and Dr Bert W O’Malley, Baylor College of Medicine, USA. Abstract Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition Key Words affecting one in four women of reproductive age. Current treatments (conservative, f abnormal uterine medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. bleeding (AUB) Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated f heavy menstrual bleeding (HMB) pathways, a hormone critical to female reproductive health and disease; therefore, f selective progesterone SPRMs hold great potential in fulfilling an unmet need in managing gynaecological receptor modulators disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed (SPRM) for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB f leiomyoma in women with leiomyomas and in a higher dose as an emergency contraceptive. In this f fibroid article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women’s quality of life.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,173,626 B2 Hausknecht (45) Date of Patent: May 8, 2012
    US008173626B2 (12) United States Patent (10) Patent No.: US 8,173,626 B2 Hausknecht (45) Date of Patent: May 8, 2012 (54) METHODS, DOSING REGIMENS AND OTHER PUBLICATIONS MEDICATIONS USING ANT-PROGESTATIONAL AGENTS FOR THE Lumsden and Wallace, Bailliere's Clinical Obstetrics and Gynaecol TREATMENT OF DISORDERS ogy, 1998; 12(2): 177-195.* Eldar-Geva, Bailliere's Clinical Obstetrics and Gynaecology, (75) Inventor: Richard Hausknecht, Bronx, NY (US) 1998; 12(2):269-288.* Chwalisz et al., Presentation at Advances in Leiomyoma Research (73) Assignee: Danco Laboratories LLC, New York, 2nd NIH International Congress, Feb. 2005, Bethesda, MD.* NY (US) Chu et al. Successful Long-Term Treatment of Refractory Cushings Disease with High-Dose Mifepristone (RU486). J. Clin. Endocrinol. (*) Notice: Subject to any disclaimer, the term of this Metab. Aug. 2001, vol. 86, No. 8, pp. 3568-3573. patent is extended or adjusted under 35 Eisinger et al., Low-Dose Mifepristone for Uterine Lelomyomata. J. U.S.C. 154(b) by 1328 days. Obstet. Gynecol., Feb. 2003, vol. 101, No. 2, pp. 243-250. Xu et al. The Journal of Clinical Endocrinology & Metabolism (21) Appl. No.: 11/715,509 90(2):953-961 (2005). NIH Record, 57(24): 1-12, Dec. 2, 2005. (22) Filed: Mar. 8, 2007 * cited by examiner (65) Prior Publication Data US 2007/021330.6 A1 Sep. 13, 2007 Primary Examiner — San-Ming Hui (74) Attorney, Agent, or Firm — Don J. Pelto, Esquire; Related U.S. Application Data Sheppard, Mullin, Richter & Hampton LLP (60) Provisional application No. 60/780,047, filed on Mar. 8, 2006. (57) ABSTRACT (51) Int.
    [Show full text]
  • Asoprisnil the Progesterone Receptor Modulator Bleeding in Women And
    Uterine NK Cells Regulate Endometrial Bleeding in Women and Are Suppressed by the Progesterone Receptor Modulator Asoprisnil This information is current as of October 2, 2021. Julia Wilkens, Victoria Male, Peter Ghazal, Thorsten Forster, Douglas A. Gibson, Alistair R. W. Williams, Savita L. Brito-Mutunayagam, Marie Craigon, Paula Lourenco, Iain T. Cameron, Kristof Chwalisz, Ashley Moffett and Hilary O. D. Critchley Downloaded from J Immunol 2013; 191:2226-2235; Prepublished online 2 August 2013; doi: 10.4049/jimmunol.1300958 http://www.jimmunol.org/content/191/5/2226 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/08/06/jimmunol.130095 Material 8.DC1 References This article cites 45 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/191/5/2226.full#ref-list-1 by guest on October 2, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • The Spectrum of Endometrial Pathology Induced by Progesterone Receptor Modulators
    Modern Pathology (2008) 21, 591–598 & 2008 USCAP, Inc All rights reserved 0893-3952/08 $30.00 www.modernpathology.org The spectrum of endometrial pathology induced by progesterone receptor modulators George L Mutter1, Christine Bergeron2, Liane Deligdisch3, Alex Ferenczy4, Mick Glant5, Maria Merino6, Alistair RW Williams7 and Diana L Blithe8 1Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Pathology, Laboratoire Pasteur-Cerba, Cergy Pontoise, France; 3Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA; 4Department of Pathology, Jewish General Hospital, Montreal, QC, Canada; 5Department of Pathology, DCL Medical Laboratories Inc., Indianapolis, IN, USA; 6Department of Pathology, National Institutes of Health, Bethesda, MD, USA; 7Department of Pathology, University of Edinburgh, Edinburgh, UK and 8The Contraception and Reproductive Health Branch, Center for Population Research, National Institute of Child Health and Human Development, Bethesda, MD, USA Progesterone receptor modulators (PRM) are hormonally active drugs effective in the management of endometriosis and uterine leiomyomata. The endometrial effects of progestin blockade by PRMs in premenopausal women are currently being evaluated in several clinical trials, but few pathologists have had access to these materials and published information of the histological changes is scanty. Eighty-four endometrial specimens from women receiving one of four different PRMs were reviewed by a panel of seven experienced gynecologic pathologists to develop consensus observations and interpretive recommendations as part of an NIH-sponsored workshop. Although the pathologists were blinded to agent, dose, and exposure interval, the review was intended to provide an overview of the breadth of possible findings, and a venue to describe unique features.
    [Show full text]
  • Tepzz 85476¥B T
    (19) TZZ ¥_T (11) EP 2 854 763 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/48 (2006.01) 26.09.2018 Bulletin 2018/39 (86) International application number: (21) Application number: 13728632.4 PCT/US2013/043447 (22) Date of filing: 30.05.2013 (87) International publication number: WO 2013/181449 (05.12.2013 Gazette 2013/49) (54) FORMULATIONS FOR VAGINAL DELIVERY OF ANTIPROGESTINS FORMULIERUNGEN ZUR VAGINALEN ABGABE VON ANTIPROGESTINEN FORMULATIONS D’ADMINISTRATION VAGINALE D’ANTIPROGESTINES (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • PODOLSKI, Joseph, S. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO The Woodlands, TX 77381 (US) PL PT RO RS SE SI SK SM TR •HSU,Kuang Designated Extension States: The Woodlands, TX 77381 (US) ME (74) Representative: Nederlandsch Octrooibureau (30) Priority: 31.05.2012 US 201261653674 P P.O. Box 29720 2502 LS The Hague (NL) (43) Date of publication of application: 08.04.2015 Bulletin 2015/15 (56) References cited: EP-A1- 1 593 376 WO-A1-2011/039680 (73) Proprietor: Repros Therapeutics Inc. US-A1- 2008 248 102 US-A1- 2011 046 098 The Woodlands, TX 77380 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Selective Progesterone Receptor Modulators (Sprms): Progesterone Receptor Action, Mode of Action on the Endometrium and Treatment Options in Gynaecological Therapies
    Edinburgh Research Explorer Selective progesterone receptor modulators (SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in gynaecological therapies. Citation for published version: Wagenfeld, A, Saunders, P, Whitaker, L & Critchley, H 2016, 'Selective progesterone receptor modulators (SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in gynaecological therapies.', Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2016.1180368 Digital Object Identifier (DOI): 10.1080/14728222.2016.1180368 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Expert Opinion on Therapeutic Targets General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 01. Oct. 2021 Expert Opinion on Therapeutic Targets ISSN: 1472-8222 (Print) 1744-7631 (Online) Journal homepage: http://www.tandfonline.com/loi/iett20 Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies Andrea Wagenfeld, Philippa T.K. Saunders, Lucy Whitaker & Hilary O.D.
    [Show full text]